Jane Robertson, BSc, MBCHB, MD
AstraZeneca
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jane Robertson, BSc, MBCHB, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 13:41 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT01081951 · Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian CancerAstraZeneca · active not recruiting · Ovarian Cancer · study director
- Ph2NCT01078662 · Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation PatsAstraZeneca · completed · Ovarian, Breast, Prostate · study director
- Ph2NCT01063517 · Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer PatientsAstraZeneca · completed · Gastric Cancer · study director
- Ph2NCT00912743 · Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) StatusAstraZeneca · completed · Colorectal Cancer · study director
- Ph1NCT00819221 · AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid TumoursAstraZeneca · terminated · Solid Tumors · study director
- Ph1NCT00782574 · Phase I AZD2281/Cisplatin in Advanced Solid Tumour PatientsAstraZeneca · completed · Advanced Solid Tumors · study director
- Ph1NCT00777582 · Phase I Comparative Bioavailability StudyAstraZeneca · active not recruiting · Solid Tumors · study director
- Ph2NCT00679783 · Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast CancerAstraZeneca · completed · Ovarian Carcinoma, Breast Cancer · study director
- Ph2NCT00628251 · Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian CancerAstraZeneca · completed · Ovarian Neoplasms · study director
- Ph1NCT00516724 · Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or PaclitaxelAstraZeneca · completed · Triple Negative Metastatic Breast Cancer, Advanced Ovarian Cancer, Carboplatin · study director
- Ph1NCT00516373 · A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)AstraZeneca · completed · Ovarian Neoplasms, BRCA1 Protein, BRCA2 Protein · study director
- Ph1NCT00515866 · Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic CancerAstraZeneca · completed · Pancreatic Neoplasms · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 13:41 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in pancreatic cancer.